title: [The effects of antiprostatic agents on the accessory sex organs of rats treated with adrenal androgens].
abstract: It is well known that some adrenal androgens are converted into testosterone and dihydrotestosterone which are more powerful androgens than the adrenal androgens. However, most of the experiments to investigate the antiprostatic agents have been done on rats which secrete only a marginal amount of adrenal androgen. A study was performed to investigate the effects of antiprostatic agents on the action of the adrenals in rats. Non-sterodidal antiandrogens flutamide and 1-chloro-2-hydroxy-2-methyl-N-(3,4,5-trichlorophenyl)propanamide (AA560), steroidal anti-androgens, chlormadinone acetate (CMA) and 17 alpha-acetoxy-6-chloro-2-oxapregna-4,6-diene-3,20-dione (TZP-4238) and 5 alpha-reductase inhibitor, sodium (-)-4[2-[2,3-dimethyl-4-[1-(4-isobutylphenyl)ethoxy]benzolamino ] phenoxy]butyrate (ONO-3805) and N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-l-ene-17 beta-carboxamide (MK-906) were tested in rats treated with dehydroepiandrosterone sulfate (DHEA-S) and androstenendione (A). In the noncastrated rats not treated with DHEA-S and A, all of these agents decreased the accessory organ weights in a dose dependent manner. In the rats treated with LHRH agonist and DHEA-S and A, all agents (3.3 mg/day) showed similar effects in intact rats. However nonsteroidal antiandrogens and TZP-4238 were stronger than the others. It was not clear whether this effect was mediated through the suppression of adrenal androgen action or the inhibition of physiological increase in testosterone caused by an LHRH agonist. The effects of Flu, ONO-3805, CMA and TZP-4238 on the accessory sex organs were investigated in castrated rats receiving DHEA-S and A.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Urology, Gunma University School of Medicine.
authors.forename: K
authors.initials: K
authors.lastname: Imai
authors.forename: O
authors.initials: O
authors.lastname: Takahashi
authors.forename: K
authors.initials: K
authors.lastname: Watanabe
authors.forename: Y
authors.initials: Y
authors.lastname: Nakazawa
authors.forename: S
authors.initials: S
authors.lastname: Nakata
authors.forename: H
authors.initials: H
authors.lastname: Yamanaka
mesh_terms: D000311:Adrenal Glands / Q000378:metabolism*; D000726:Androgen Antagonists / Q000494:pharmacology*; D000728:Androgens / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D002369:Castration; D013196:Dihydrotestosterone / Q000378:metabolism; D005485:Flutamide / Q000494:pharmacology; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006801:Humans; D016729:Leuprolide / Q000494:pharmacology; D008297:Male; D009929:Organ Size; D011467:Prostate / Q000187:drug effects* / Q000473:pathology; D051381:Rats; D011919:Rats, Inbred Strains; D013739:Testosterone / Q000378:metabolism
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D013196:Dihydrotestosterone; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D005485:Flutamide; D016729:Leuprolide